These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 2934234)

  • 21. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A
    Scand J Infect Dis; 1985; 17(1):91-4. PubMed ID: 3158070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Petermüller C
    Eur J Clin Microbiol; 1983 Apr; 2(2):111-5. PubMed ID: 6222896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
    Soussy CJ; Deforges L; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
    Gargallo D; Moros M; Coll R; Esteve M; Parés J; Xicota MA; Guinea J
    Antimicrob Agents Chemother; 1988 May; 32(5):636-41. PubMed ID: 3134844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H
    Infection; 1986; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
    Digranes A; Benonisen E; Salveson A; Zahm F
    Chemotherapy; 1988; 34(5):401-10. PubMed ID: 3141116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of pefloxacin compared with six other quinolones.
    Ligtvoet EE; Wickerhoff-Minoggio T
    J Antimicrob Chemother; 1985 Oct; 16(4):485-90. PubMed ID: 3864776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
    Allocati N; Catamo G; Cellini L
    Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1927-33. PubMed ID: 6440583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Aug; 6(4):482-5. PubMed ID: 3117538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1983 Jun; 1(2):165-72. PubMed ID: 6232084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.
    Wise R; Andrews JM; Ashby JP; Matthews RS
    Antimicrob Agents Chemother; 1988 May; 32(5):617-22. PubMed ID: 3134843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.
    Kenny GE; Hooton TM; Roberts MC; Cartwright FD; Hoyt J
    Antimicrob Agents Chemother; 1989 Jan; 33(1):103-7. PubMed ID: 2712541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
    Barry AL; Jones RN; Thornsberry C; Ayers LW; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1984 May; 25(5):633-7. PubMed ID: 6233935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro effect of rosoxacin on hospital bacteria. Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Chanal M; Cluzel M; Fleurette J; Forey F; Thabaut A; Meyran M; Vandekerkove M; Sicard D; Acar JF; Kitzis MD; Veron M; Fauchere JL
    Pathol Biol (Paris); 1983 Jun; 31(6):504-8. PubMed ID: 6348657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.
    Peeters M; Van Dyck E; Piot P
    Antimicrob Agents Chemother; 1984 Oct; 26(4):608-9. PubMed ID: 6240224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in-vitro comparative activity of quinolones against bacteria from urinary tract infections in general practice.
    Willems FT; Boerema JB; von Summeren TR
    J Antimicrob Chemother; 1986 Jan; 17(1):69-73. PubMed ID: 2936709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.